These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 30127628)

  • 1. Optimal infusion rate in antimicrobial therapy explosion of evidence in the last five years.
    Zhu LL; Zhou Q
    Infect Drug Resist; 2018; 11():1105-1117. PubMed ID: 30127628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis.
    Prescott WA; Gentile AE; Nagel JL; Pettit RS
    P T; 2011 Nov; 36(11):723-63. PubMed ID: 22346306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.
    Koomanachai P; Bulik CC; Kuti JL; Nicolau DP
    Clin Ther; 2010 Apr; 32(4):766-79. PubMed ID: 20435246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
    Yost RJ; Cappelletty DM;
    Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
    Kim A; Kuti JL; Nicolau DP
    Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing Antibiotic Treatment Strategies for Neonates and Children: Does Implementing Extended or Prolonged Infusion Provide any Advantage?
    Costenaro P; Minotti C; Cuppini E; Barbieri E; Giaquinto C; Donà D
    Antibiotics (Basel); 2020 Jun; 9(6):. PubMed ID: 32560411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
    Sun HK; Kuti JL; Nicolau DP
    Crit Care Med; 2005 Oct; 33(10):2222-7. PubMed ID: 16215374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
    Xiao YH; Hu YJ
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
    Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
    Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(11):1135-75. PubMed ID: 11735679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
    Taccone FS; Laterre PF; Dugernier T; Spapen H; Delattre I; Wittebole X; De Backer D; Layeux B; Wallemacq P; Vincent JL; Jacobs F
    Crit Care; 2010; 14(4):R126. PubMed ID: 20594297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic profiling of antimicrobials against Gram-negative respiratory isolates from Canadian hospitals.
    Keel RA; Zhanel GG; Zelenitsky S; Nicolau DP
    Can J Infect Dis Med Microbiol; 2011; 22(4):132-6. PubMed ID: 23205024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial.
    Hagel S; Fiedler S; Hohn A; Brinkmann A; Frey OR; Hoyer H; Schlattmann P; Kiehntopf M; Roberts JA; Pletz MW;
    Trials; 2019 Jun; 20(1):330. PubMed ID: 31171029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics.
    Chen M; Buurma V; Shah M; Fahim G
    Am J Health Syst Pharm; 2019 Sep; 76(18):1383-1394. PubMed ID: 31505562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of antimicrobial resistance to piperacillin/tazobactam or meropenem in the ICU: Intermittent versus continuous infusion. A retrospective cohort study.
    Dhaese SAM; De Kezel M; Callant M; Boelens J; De Bus L; Depuydt P; De Waele JJ
    J Crit Care; 2018 Oct; 47():164-168. PubMed ID: 30005302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS; Loeb M; Leto D; Brooks AA
    Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
    Goff DA; Nicolau DP
    Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compatibility of prolonged infusion antibiotics during Y-site administration.
    Nunez-Nunez M; Murillo-Izquierdo M; Moya-Martin M; Hoxha M; Quesada Pérez MT; Oltra-Hostalet F; Alonso-Ramos H; Cordero-Ramos J; Barrera-Cabeza J; Retamar-Gentil P; Fernández-Del-Castillo SS
    Nurs Crit Care; 2022 Nov; 27(6):849-858. PubMed ID: 35088491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
    Zarakolu P; Hasçelik G; Unal S
    Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.